scholarly journals Impact of Antiviral Prophylaxis Duration On Varicella Zoster Virus Infection Rates in Recipients of Autologous Hematopoietic Cell Transplantation

2013 ◽  
Vol 19 (2) ◽  
pp. S190-S191
Author(s):  
Quoc Truong ◽  
Lauren Veltri ◽  
Abraham Kanate ◽  
Mehdi Hamadani ◽  
Michael Craig ◽  
...  
Keyword(s):  
Virus Infection ◽  
Varicella Zoster Virus ◽  
Cell Transplantation ◽  
Hematopoietic Cell Transplantation ◽  
Hematopoietic Cell ◽  
Varicella Zoster Virus Infection ◽  
Antiviral Prophylaxis ◽  
Infection Rates ◽  
Varicella Zoster ◽  
Autologous Hematopoietic Cell Transplantation

scholarly journals Pseudo-bowel obstruction due to varicella zoster virus infection after autologous stem cell transplantation

2009 ◽  
Vol 84 (2) ◽  
pp. 127-128 ◽  
Author(s):  
Cristina Mihaela Precupanu ◽  
Jacques Girodet ◽  
Pascale Mariani ◽  
Manuela Zanni ◽  
Claire Mathiot ◽  
...  
Keyword(s):  
Stem Cell ◽  
Virus Infection ◽  
Stem Cell Transplantation ◽  
Varicella Zoster Virus ◽  
Cell Transplantation ◽  
Autologous Stem Cell Transplantation ◽  
Bowel Obstruction ◽  
Varicella Zoster Virus Infection ◽  
Varicella Zoster

scholarly journals Long-term acyclovir for prevention of varicella zoster virus disease after allogeneic hematopoietic cell transplantation—a randomized double-blind placebo-controlled study

Blood ◽  
2006 ◽  
Vol 107 (5) ◽  
pp. 1800-1805 ◽  
Author(s):  
Michael Boeckh ◽  
Hyung W. Kim ◽  
Mary E. D. Flowers ◽  
Joel D. Meyers ◽  
Raleigh A. Bowden
Keyword(s):  
Varicella Zoster Virus ◽  
Cell Transplantation ◽  
Hematopoietic Cell Transplantation ◽  
Hematopoietic Cell ◽  
Cell Transplant ◽  
Transplant Recipients ◽  
Hematopoietic Cell Transplant ◽  
Double Blind ◽  
Varicella Zoster ◽  
Cmv Disease

Varicella-zoster virus (VZV) disease occurs in 30% of allogeneic hematopoietic cell transplant recipients who had a history of VZV infection. A safe and effective prevention strategy has not been established. In a double-blind controlled trial, 77 hematopoietic cell transplant recipients at risk for VZV reactivation were randomized to acyclovir 800 mg twice daily or placebo given from 1 to 2 months until 1 year after transplantation. VZV disease at 1 year was the primary end point; VZV disease after discontinuation of prophylaxis, VZV-specific T-cell immunity, herpes simplex virus (HSV) infection, cytomegalovirus (CMV) disease, survival, and safety were secondary end points. Acyclovir significantly reduced VZV infections at 1 year after transplantation (HR, 0.16; 95% CI, 0.035-0.74; P = .006). In the postintervention observation period, this difference was not statistically significant (2 years: HR, 0.52; 95% CI, 0.21-1.3; 5 years: HR, 0.76; 95% CI, 0.36-1.6). There was no statistically significant difference in reconstitution of VZV-specific T-helper cell responses, HSV infections, CMV disease, chronic graft-versus-host disease, and overall survival between the groups. Acyclovir was well tolerated. Post-study VZV disease predominantly occurred in patients with continued need for systemic immunosuppression. In conclusion, acyclovir effectively and safely prevents VZV disease during the first year after hematopoietic cell transplantation. Periods of prophylaxis longer than 12 months may be beneficial for those hematopoietic cell transplant recipients on continued immune suppression.

Sign in / Sign up

Export Citation Format

Share Document